Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 10/20 | 0.53 |
| ▸ | NR1H3 | Q13133 | 7/20 | 0.53 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.47 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.41 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.41 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL522583 | 0.93 | NR1H2 (0.53) | NR1H2NR1H3ROCK2ABHD6GPR119 | |
| SCHEMBL521801 | 0.85 | NR1H2 (0.49) | NR1H2NR1H3ROCK2ABHD6GPR119 | |
| SCHEMBL4712983 | 0.85 | NR1H2 (0.58) | NR1H2NR1H3ROCK2ABHD6GPR119 | |
| SCHEMBL31226555 | 0.84 | RIPK1 (0.53) | NR1H2NR1H3GPR119USP30 | |
| SCHEMBL21207072 | 0.84 | RIPK1 (0.53) | NR1H2NR1H3GPR119USP30 | |
| SCHEMBL4718386 | 0.84 | RIPK1 (0.53) | NR1H2NR1H3GPR119USP30 | |
| SCHEMBL21198773 | 0.84 | RIPK1 (0.53) | NR1H2NR1H3GPR119USP30 | |
| SCHEMBL25320429 | 0.83 | RIPK1 (0.49) | NR1H2NR1H3GPR119 | |
| SCHEMBL31226567 | 0.83 | RIPK1 (0.49) | NR1H2NR1H3GPR119 | |
| SCHEMBL31226730 | 0.83 | RIPK1 (0.49) | NR1H2NR1H3GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2376491-B1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON INC (US) | 2015-03-04 | — | — | EP | disclosed |
| US-8471005-B2 | Pyrrolotriazines as ALK and JAK2 inhibitors | CEPHALON, INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| EP-2376491-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | Cephalon, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010071885-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | JAK2, ALK, ABL1 | NR1H2 3126/4885NR1H3 3733/4885ROCK2 467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.